Efficacy of Dexamethasone to Improve Clinical Outcomes in Coronary Artery Bypass Patients
Efficacy of Dexamethasone to Improve Clinical Outcomes in Coronary Artery Bypass Patients
NCT ID: NCT05487508 Phase: PHASE4 Status: COMPLETED Enrollment: 120 Completion: 2019-03-31
Conditions
Coronary Artery Disease, Inflammatory Response
Interventions
Dexamethasone, Normal saline
Summary
This is a single-center, double-blind, randomized controlled clinical trial comparing four groups: placebo conventional coronary artery bypass graft (CCABG) group, dexamethasone CCABG group, placebo off-pump coronary artery bypass (OPCAB) group, and dexamethasone OPCAB group. The primary outcomes of this study is comprised of presence of arrhythmia, major adverse cardiac events (MACE), myocardial infarction, stroke, renal failure, respiratory failure, inflammation, and death. These primary outcomes were assessed during the surgery, 18 hours post surgery, every day during the hospital stay, 14 days and 30 days post surgery.
Primary Outcome
Presence of arrhythmia as seen on EKG